NPPB and type 2 diabetes mellitus: Similarly, in the NT-proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC) study, enrolling 300 patients with type 2 diabetes and NT-proBNP > 125 ng/L with no structural heart disease, a strategy based on rapid titration of RAAS inhibitors and beta-blockers significantly reduced the primary endpoint of hospitalization or death from cardiovascular causes at 2 years (HR 0.35 [0.13–0.98], p = 0.04) compared to standard follow-up [33].